Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18170578 | 0.96 | NPC1 (0.53) | F10GSK3BKDRKCNK9RAB9A | |
| SCHEMBL18170485 | 0.89 | KDR (0.58) | GSK3BKDRKCNK9MEN1KMT2A | |
| SCHEMBL18170633 | 0.89 | NPC1 (0.56) | KDRKCNK9RAB9ANPC1MEN1 | |
| SCHEMBL18170682 | 0.89 | RAB9A (0.56) | KDRKCNK9RAB9ANPC1MEN1 | |
| SCHEMBL18170542 | 0.88 | KDR (0.58) | KDRRAB9ANPC1MEN1KMT2A | |
| SCHEMBL18170782 | 0.86 | KDR (0.56) | F10GSK3BKDRMEN1KMT2A | |
| SCHEMBL18170461 | 0.86 | MEN1 (0.52) | KDRKCNK9RAB9ANPC1MEN1 | |
| SCHEMBL18170505 | 0.85 | KDR (0.60) | F10GSK3BKDRRAB9ANPC1 | |
| SCHEMBL18170586 | 0.85 | KDR (0.49) | GSK3BKDRRAB9ANPC1MEN1 | |
| SCHEMBL18170949 | 0.84 | KDR (0.61) | KDRRAB9ANPC1ADORA3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | claimed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | claimed |
| US-9856216-B2 | Compounds as TNIK, IKKε and TBK1 inhibitors and pharmaceutical composition comprising same | GREEN CROSS CORPORATION (KR) | 2018-01-02 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | GREEN CROSS CORPORATION (KR) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311772-A1 | COMPOUNDS AS TNIK, IKKEPSILON AND TBK1 INHIBITORS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | TNIK, TNK1, NFKBIA | F10 3796/4885GSK3B 564/4885KDR 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.